|تاریخ چاپ: 1399/05/13|
|Does fibroblast growth factor 23 correlates with volume status inhemodialysis patients?|
|Author(s):||Farzanehsadat Minoo، Azam Alamdari*، Hamed Karimi|
Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies.
This is a prospective cross-sectional study considering the association between FGF23 and bioimpedance-measured volume overload in hemodialysis patients.
Patients and Methods
Bioimpedance analysis was performed on 43 hemodialysis patients at the end of hemodialysis to evaluate the remaining volume overload and serum FGF23 was measured before hemodialysis.
The results indicated no significant correlation between mean serum FGF23 levels and volume overload in hemodialysis patients (P=0.824).
Although this study did not show any association between volume overload and FGF23, further studies are needed to define the role of FGF23 as a volume overload marker.
|Keywords:||Fibroblast growth factor 23، Hemodialysis، Volume status، Overload، Bio-impedance analysis، Chronic kidney diseas|
|Article Type:||Research/Original Article|
|Published:||Journal of nephropathology, Volume:8 Issue: 4, 2019|
|Full text:||PDF is available on the website.|